title: Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients.
abstract: A sensitive and relatively specific tumoral marker for lung epidermoid carcinomas could be used to identify patients likely to benefit from new therapeutic protocols. The cyfra 21-1 fragment of cytokeratin 19 has raised much hope in this regard amongst both technologists and clinicians. In a study of 195 subjects, we have shown by means of a serum assay that the usual cut-off value for this marker (3.3 ng/ml) can be lowered to 1.5 ng/ml without loss of specificity, and with an increase in sensitivity. There was a good correlation between serum marker level and tumor extension, but though cyfra 21-1 was not predictive of the suitability of a patient for surgery. A decrease of cyfra-21-1 was observed after complete resection of the tumor. There was no relation between serum assay results and immunohistochemical findings.
authors.affiliation: Centre de Lutte Contre le Cancer Eugène Marquis, Département de Biologie Clinique et Expérimentale, Rennes, France.
authors.forename: V
authors.initials: V
authors.lastname: Quillien
authors.forename: M P
authors.initials: MP
authors.lastname: Ramee
authors.forename: J Y
authors.initials: JY
authors.lastname: Bansard
authors.forename: H
authors.initials: H
authors.lastname: Meritte
authors.forename: E
authors.initials: E
authors.lastname: Briens
authors.forename: Y
authors.initials: Y
authors.lastname: Logeais
authors.forename: T
authors.initials: T
authors.lastname: Langanay
authors.forename: H
authors.initials: H
authors.lastname: Corbineau
authors.forename: L
authors.initials: L
authors.lastname: Dazord
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000737:chemistry / Q000150:complications / Q000473:pathology / Q000601:surgery; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D018288:Carcinoma, Small Cell / Q000097:blood / Q000737:chemistry / Q000150:complications / Q000473:pathology / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000737:chemistry / Q000150:complications / Q000473:pathology / Q000601:surgery; D006801:Humans; D007124:Immunoenzyme Techniques; D007633:Keratins / Q000032:analysis* / Q000097:blood; D008171:Lung Diseases / Q000097:blood / Q000150:complications; D008175:Lung Neoplasms / Q000097:blood / Q000737:chemistry* / Q000150:complications / Q000473:pathology / Q000601:surgery; D009336:Necrosis; D009363:Neoplasm Proteins / Q000032:analysis* / Q000097:blood; D009367:Neoplasm Staging; D011184:Postoperative Period; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D014376:Tuberculosis / Q000097:blood
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D007633:Keratins